Market cap
₹37 Cr
Revenue (TTM)
₹70 Cr
P/E Ratio
20.8
P/B Ratio
1
Div. Yield
2.6 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -2.75 | -1.86 | 4.16 | 1.40 | 1.57 |
| EBIT | -8.33 | 8.09 | 7.40 | 5.45 | 2.36 |
| Net Profit | 430.23 | 2.24 | 10.34 | 6.48 | 2.45 |
| EPS | 430.34 | 2.25 | 10.34 | 6.48 | -2.53 |
| Book Value | -- | -- | 5.37 | -3.52 | 4.25 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Mar-26 | Mar-25 |
| EBIT-Margin
| 2.99 | 3.12 | 3.38 | 3.32 | 3.11 |
| Net Margin
| 2.32 | 2.34 | 2.53 | 2.51 | 2.30 |
| Return on equity
| 4.66 | 4.98 | 4.12 | 5.14 | 4.74 |
| Return on Capital
| 6.99 | 7.44 | -- | 8.06 | 6.91 |
| Return on Assets
| 2.92 | 3.00 | 3.17 | 3.17 | 2.86 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.00 | 0.00 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
--
|
8.06
|
6.91
|
6.00
|
6.89
|
|
Peer Median
|
--
|
16.69
|
14.23
|
13.72
|
--
|
ROE
4.12
Higher than Peers by 0.51
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
4.12
|
5.14
|
4.74
|
4.11
|
4.60
|
|
Peer Median
|
3.61
|
13.78
|
9.34
|
9.55
|
--
|
ROA
3.17
Higher than Peers by 0.43
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
3.17
|
3.17
|
2.86
|
2.74
|
2.95
|
|
Peer Median
|
2.74
|
9.65
|
5.46
|
5.81
|
--
|
EBIT Margin
3.38
Higher than Peers by 0.17
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
3.38
|
3.32
|
3.11
|
2.55
|
3.02
|
|
Peer Median
|
3.21
|
21.68
|
--
|
12.51
|
--
|
Net Margin
2.53
Higher than Peers by 0.37
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
2.53
|
2.51
|
2.30
|
2.16
|
2.32
|
|
Peer Median
|
2.16
|
7.13
|
3.10
|
3.56
|
--
|
Cash Profit Margin
--
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
--
|
3.49
|
3.30
|
3.04
|
3.12
|
|
Peer Median
|
--
|
0.00
|
--
|
0.00
|
--
|
Revenue Growth
4.16
Lower than Peers by 8.95
Year on year growth in net sales
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
4.16
|
4.08
|
-0.13
|
2.96
|
-0.23
|
|
Peer Median
|
13.11
|
59.91
|
--
|
38.08
|
--
|
EBIT Growth
7.40
Higher than Peers by 7.04
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
7.40
|
11.08
|
22.01
|
-13.10
|
-15.84
|
|
Peer Median
|
0.36
|
58.30
|
--
|
460.14
|
--
|
Net Profit Growth
10.34
Higher than Peers by 12.78
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
10.34
|
14.03
|
6.04
|
-4.15
|
-4.12
|
|
Peer Median
|
-2.44
|
57.78
|
--
|
-3.95
|
--
|
EPS Growth
10.34
--
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
10.34
|
14.03
|
6.04
|
-4.15
|
-12.55
|
|
Peer Median
|
--
|
11.46
|
--
|
90.91
|
--
|
Book Value Growth
--
--
Year on year growth in book value per share
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
--
|
5.37
|
4.89
|
-18.74
|
45.06
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
0.04
|
0.04
|
0.00
|
--
|
Short term debt to equity ratio
--
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
2.43
Higher than Peers by 0.41
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
2.43
|
2.43
|
2.18
|
2.10
|
1.84
|
|
Peer Median
|
2.02
|
2.56
|
2.10
|
2.00
|
--
|
Quick Ratio
1.42
Higher than Peers by 0.19
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
1.42
|
1.42
|
1.01
|
0.94
|
0.81
|
|
Peer Median
|
1.23
|
2.33
|
--
|
3.80
|
--
|
Interest Coverage
23.89
Higher than Peers by 16.21
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
23.89
|
24.71
|
21.87
|
33.84
|
28.89
|
|
Peer Median
|
7.68
|
34.74
|
16.23
|
8.29
|
--
|
Operating Efficiency
Debtors to sales
7.77
Lower than Peers by 7.47
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
7.77
|
7.74
|
7.08
|
7.24
|
7.33
|
|
Peer Median
|
15.24
|
16.30
|
--
|
27.50
|
--
|
Asset Turnover
1.25
Higher than Peers by 0.01
Sales / Average Total Assets
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
1.25
|
1.25
|
1.24
|
1.26
|
1.26
|
|
Peer Median
|
1.24
|
2.28
|
--
|
1.26
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
--
|
26.53
|
26.14
|
26.20
|
24.53
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
--
|
64.25
|
71.70
|
72.09
|
71.49
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
--
|
51.77
|
49.36
|
70.55
|
89.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
--
|
39.02
|
48.49
|
27.74
|
6.99
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
20.84
No difference
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
20.84
|
16.69
|
30.56
|
37.96
|
33.09
|
|
Peer Median
|
20.84
|
20.33
|
30.84
|
47.94
|
--
|
Price / Book Value
1.04
No difference
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
1.04
|
0.84
|
1.41
|
1.74
|
1.29
|
|
Peer Median
|
1.04
|
2.72
|
6.38
|
4.56
|
--
|
Dividend Yield
2.62
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
2.62
|
3.28
|
1.63
|
1.39
|
1.44
|
|
Peer Median
|
--
|
0.25
|
--
|
0.08
|
--
|
EV/EBITDA
8.69
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
8.69
|
6.57
|
15.25
|
19.95
|
17.09
|
|
Peer Median
|
--
|
14.82
|
30.04
|
35.83
|
--
|
Market Cap
37
Lower than Peers by 32
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
|---|---|---|---|---|---|
|
Sandu Pharma
|
37
|
29
|
47
|
55
|
50
|
|
Peer Median
|
69
|
199
|
268
|
133
|
--
|